Merck

@Merck

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: merck.us/3TKXNuZ

Rahway, NJ

Merck
@Merck
Oct 26
Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more: go.merck.com/~82i
00:00
Merck
@Merck
Oct 26
Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO.
00:00
1
Merck
@Merck
Oct 22
We announced positive Phase 3 data for our investigational individualized neoantigen therapy in combination with our company’s immunotherapy for patients with completely resected stage IIB-IV #melanoma in collaboration with @moderna_tx. Read more: go.merck.com/~km1
00:00
4
Merck
@Merck
Oct 21
Today, the European Commission approved a combination regimen for adults with muscle-invasive #BladderCancer (MIBC). Learn more about how we're helping advance cancer care with Pfizer and Astellas: go.merck.com/~oa7
00:00
1
Merck
@Merck
Oct 13
We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer
00:00
6